News from alkermes plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

20 May, 2020, 12:00 BST Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia

Alkermes plc (Nasdaq: ALKS) today announced that data from its phase 3b ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation...


14 May, 2020, 12:00 BST Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society

Alkermes plc (Nasdaq: ALKS) today announced the presentation of new data from its schizophrenia portfolio as part of the virtual 2020 Congress of the ...


11 May, 2020, 12:00 BST Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis

Alkermes plc (Nasdaq: ALKS) today announced the expansion of several programs and services in support of patient access to its proprietary medicines...


06 May, 2020, 21:00 BST Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 2020 Bank of America Securities Virtual Health ...


04 May, 2020, 12:00 BST Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities

Alkermes plc (Nasdaq: ALKS) today announced that the company is now accepting applications for its newly-established COVID-19 Relief Fund, a special...


29 Apr, 2020, 12:00 BST Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update

Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2020, and provided commentary related to the impact of the...


22 Apr, 2020, 21:00 BST Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 29, 2020 to...


22 Apr, 2020, 12:00 BST Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer

Alkermes plc (Nasdaq: ALKS) today announced the publication of preclinical data demonstrating the selectivity and anti-tumor efficacy of its...


04 Mar, 2020, 12:00 GMT Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia

Alkermes plc (Nasdaq: ALKS) today announced the publication of results from the phase 3 ENLIGHTEN-1 clinical trial of ALKS 3831...


24 Feb, 2020, 21:00 GMT Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will present at the Cowen and Company 40th Annual Health...


19 Feb, 2020, 21:01 GMT Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on...


13 Feb, 2020, 12:00 GMT Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2019 and provided financial expectations for...


06 Feb, 2020, 21:00 GMT Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 13, 2020, to...


28 Jan, 2020, 12:00 GMT Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug...


08 Jan, 2020, 21:00 GMT Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference ...


26 Nov, 2019, 21:01 GMT Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Evercore ISI...


25 Nov, 2019, 12:00 GMT Alkermes Completes Acquisition of Rodin Therapeutics

Alkermes plc (Nasdaq: ALKS) today announced that it has completed its previously announced acquisition of Rodin Therapeutics, Inc. (Rodin), a...


19 Nov, 2019, 12:00 GMT Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder

Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...


18 Nov, 2019, 12:00 GMT Alkermes to Acquire Rodin Therapeutics

Alkermes plc (Nasdaq: ALKS) and Rodin Therapeutics, Inc. (Rodin) today announced that they have entered into a definitive agreement under which...


12 Nov, 2019, 21:01 GMT Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Stifel 2019 Healthcare Conference on Tuesday, ...


12 Nov, 2019, 12:00 GMT Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™

Alkermes plc (Nasdaq: ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug...


08 Nov, 2019, 12:00 GMT Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Alkermes plc (Nasdaq: ALKS) today presented new data from the company's ARTISTRY clinical development program related to ALKS 4230 at the Society for ...


04 Nov, 2019, 12:00 GMT Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced that it will present new data from its ARTISTRY clinical development program related to ALKS 4230, an...


30 Oct, 2019, 11:30 GMT Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™...


23 Oct, 2019, 12:00 BST Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2019 and the implementation of a restructuring plan following a ...